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A bacterial strain belonging to the genus Bacillus islolated by enriclunent culture technique using morphine
as a sole source of carbon transforms morphine and codeine into 14-hydroxymorphinone and 14-
hydroxycodeinone as major and 14-hydroxymorphine and 14-hydroxycodeine as minor metabolites, respectively.
When the N-methyl group in morphine and codeine are replaced by higher alkyl groups, the organism still
retains its ability to carry out 14-hydroxylation as well as oxidation of the Cs-hydroxyl group in these N- -
variants, although the level of metabolites formed are considerably low. The organism readily transforms
dihydromorphine and dihydrocodeine into only dihydromorphinone and dihydrocodeinone, respectively;
suggesting that the 7,8-double bond is a necessary structural feature to carry out 14-hydroxylation reaction. The
cell free extract (20,000 x g supernatant), prepared from morphine grown cells, transforms morphine into 14-
hydroxymorphinone in the presence ofNAD+, but fails to show activity against testosterone. However, the cell
free extract prepared from testosterone grown cells contains significant levels of 17p- hydroxysteroid
dehydrogenase but shows no activity against morphine.
n view of the difficulties associated with the synthesis of
morphine alkaloids based pharmaceutically important
compounds, several investigators explored the
possibility of using microbes as an alternate method.
Microbial transformations of morphine alka-loids have
been studied using both bacterial and fungal strains. It
was demonstrated earlier that Trametes sanguinea
converts thebaine into 14-hvdro>..'vcodeinone and 14-
hydroxycodeine'. The fonn~tion ~f these metabolites
suggests the ability of fungi to carry out allylic
ox-ygenation, and O-demethylation. Fungal strains were
also shown to carry out N-demethylation of codeine",
thebaine and its N-variants3 and N-oxidation of
codeinone". Bacterial N-demethvlation of codeine to
norcodeine'' has also been - documented earlier.
However, there are very few reports on the microbial
transformation of morphine. Transformation of
morphine into l-t-hydroxymorphine by resting cells as
well as cell-free system of Arthrobacter sp. has been
reported". Morphinone and dihydromorphinone have
also been identified as intermediates in the metabolism
of morphine by Pseudomonas putida M107 The present
paper describes the transformation of morphine,
codeine, their N-variants, dihyromorphine and dihydro-
codeine by a Bacillus sp. culture.
Materials and Methods
Microorganism. The organism used in this study was
isolated from soil using morphine as the sole source of
carbon. The organism was identified as a Bacillus sp.
Chemicals. Morphine 1, codeine 2 and thebaine were
procured from Government Opium and Alkaloid works,
Ghazipur, India. N-Alkyl variants of morphine and
codeine" dihydromorphine and dihydrocodeine", 14-
hydroxycodeinone' 0, 14-hydrox-ymorphine, 14-hydrox)'-
codeine and 14-hydro~)'morphinonell were prepared as
described earlier.
Analytical methods. Thin layer chromatographic
(TLC) analyses were performed on silica gel-G plates
(0.5mm) developed with either 15% methanol in
chloroform (system I) or 8% methanol in chloroform
(system II). HPLC analyses were carried out on a
Water Associates ALC/GPC 244 series instrument
using a u-Bondapak C18 (ODS) analytical column (300
/x 3.9 mm). The mobile phase used for the analysis was
the same as reported earlier!". Steroids were analysed
on normal phase silica gel column using 2% methanol
in chloroform. The metabolites formed were quantified
on the basis of area under each peak.
Protein was estimated by the method of Lowry et a/13.
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Fermentation conditions. The organism was
propagated on nutrient agar slants which contained 1%
peptone, 0.5% beef extract and 2% agar. Although the
organism used morphine as the sole source of carbon,
the growth rate was slow. To enhance the growth rate,
0.1% glucose was added to the medium. Fermentations
were carried out in a liquid mineral salts medium"
containing 0.1% glucose and the substrate (0.03% of
112; 0.02% of 3-8; added in 0.2-0.3 mL methanol).
Flasks were inoculated with 5% of 48hr grown culture
(~= 1.3) and incubated on a rotary shaker (220 rpm)
at 29-30 °C for 5 days.
Extraction of metabolites. At the end of the incubation
period, the contents from all the flasks were pooled,
basified to pH 9.0 using 2N NH40H and extracted with
chloroform-methanol (2:1). The organic layer was dried
over sodium suphate and concentrated in vacuo. The
crude extract was then subjected to silica gel column
chromatography.
Spectral studies. Nuclear magnetic resonance (NMR)
and mass spectra (MS) were recorded as described
earlier".
Preparation of cell-free extract. Erlenymeyer flasks
containing mineral salts medium (100 ml.), glucose
(0.1%), morphine (0.015%) were inoculated from a 2-
day grown inoculum (5%, A660=1.3) and were
incubated at 29-30 °C on a rotary shaker for 48hr. At
the end of incubation period, the cells were harvested
(3,000 x g, 20 min), washed with phosphate buffer (10
mM, pH 7.2) and suspended in phosphate buffer (50
mM, pH 8.0) containing 10% glycerol, 1mAl DTf and
1 mM EDTA at a final concentration of 0.2 glmL cell
wet weight. The cell suspension was then sonicated
using a Branson B-30 sonifier for 4 min. with
intermittent cooling for every 30 sec. at maximum
output. The sonicate was centrifuged at 3,000 x g for 3D
min. The supernatant thus obtained was further
centrifuged at 20, 000 xg for 30 min. The 20,000 x g
supernatant was dialyzed (l8hr) against phosphate
buffer (50 mM, pH 8.0) containing 10% glycerol, 1 mM
DTf and 1 mM EDTA. The dialyzed 20,000 x g
supernatant was referred as crude cell-free extract. In a
similar way cell-free extracts were prepared from cells
grown in the presence of testosterone (0.02%) and
glucose (0.2%).
Incubation conditions. The incubation mixture
contained 50 mM phosphate buffer (PH 8.0),10%
glycerol, I mAl DTf, 1 mM EDTA, morphine or
testosterone (0,15 umol in 50 ul, of methanol), cell-free
extract (4 mg ) and NAD+ (0.2 umol) in a total volume
of 2.0 mL. Reaction was started by the addition of
NAD+and incubated for l hr at 29-30 °C on a rotary
shaker. At the end of the incubation period the reaction
mixture was extracted with (2: 1) chloroform-methanol
(for alkaloids) or with methylene chloride (for steroids),
dried over anhydrous Na2S04 and evaporated to
dryness. The residue was subjected to TLC and HPLC
analyses.
Results
Transformation of morphine 1. A batch of 30 flasks
fermentation was carried out as descried in "Materials
and Methods". At the end of incubation, the contents of
the flasks were pooled and processed as described. The
curde extract (860 mg) on examination by TLC (system
I) revealed the presence of one major (R, 0.72) and one
minor (R, 0.50) metabolites. The crude extract was
subjected to column chromatography over silica gel (25
g) and the compounds with R; 0.72 (la) and 0.5 (lb)
were eluted from the column using 2% and 5%
methanol in chloroform, respectively. The compounds
Ia and 1b were further purified by preparative TLC
(system I). Based on spectral characteristics (Table 1)
and by comparing the spectral data with those of
authentic samples, la and Ib were identified as 14-
hydroxymorphinone and l-t-hydroxymorphine. respec-
tively (Scheme I).
Transformation of codeine 2. Transformation of 2
was carried out in 24 flasks as described in "Materials
and Methods". The crude extract (804 mg ) on TLC
analysis (system II) revealed the presence of one major
(Rr 0.78) and one minor (Rf 0.59) metabolites. The
crude extract was subjected to column chromatography
over silica gel (30 g) and the compounds with R; 0.78
(2a, 200mg) and 0.59 (2b, 18 mg) were eluted from the
column using 1% and 3% methanol in chloroform,
respectively. These compounds (2a and 2b) were
further purified by preparative TLC (system II). The
compounds 2a and 2b were identified as 14-
hydroxycodeinone and 14-hydroxl'codeine. respectively
by comparing their spectral data (Table I) with those of
authentic samples.
Transformation of morphine analogues 3-6.
Transformations of N-ethylnormorphine 3, N-
proplynormorphine 4, N-butylnormorphine 5 and N-
ethylnorcodeine 6 were carried out as described in
"Materials and Methods". The crude extracts (from a
batch ofS flasks) obtained from all these incubations
(3:125mg; 4:120mg; 5:1IOmg; 6:132 mg) upon TLC
analyses (system I) revealed the presence of one
metabolite ( 3a, 4a, Sa, and 6a) in each case besides the
unreacted substrate. Metabolites 3a-6a were separated
by silica gel column chromatography using 1-2%
methanol in chloroform. On the basis of various
spectral analyses (Table I), the metabolites were
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identified as 14-hydroxy-N-enthylnormorphinone 3a,
14-hydroxy-N-propylnormorphinone 4a, 14-hydroxy-N-
butylnormorphinone Sa and 14-hydroxy-N-ethylnorco-
deinone 6a (Scheme I).
Transformation of dihydromorphine 7 and dihydro-
codeine 8.
Incubations were carried out using 5 flasks for each
substrate as described in "Materials and Methods".
Substrate (0.02%) was added after 24hr of growth and
incubation continued for a further period of 5 days. At
the end of incubation period, the contents of the flasks
were extracted as described. The crude extracts
(7:96mg, 8:85mg) on TLC examination revealed the
presence of one metabolite (7a, Rr 0.31, system I; 8a, Rr
0.39, system II) in each case besides the unreacted
substrate. The metabolites were purified by silica gel
column chromatography using 1-3% methanol in
chloroform. Based on the spectral data (Table I) 7a and
Table 1.-Proton nuclear magnetic resonance ('H NMR) and mass spectral data of the metabolites la-8a.
Compd 'H NMR (8) CDCb MS (LR & HRMS)
la 6.5-6.8(3H,m,Ar-H,H-8), 6.12(1H,d, lOHz,H-7), 4.68(1 H,s,H-5)
3.2(2H,m, H-9, Hp-IO), 2.6(IH,m, Ha-IO), 2.5(3H,s,N-CH3),
2.3(2H,t,H-16), 1.6(2H, m, H-15)
Ib 6.5(2H,ABq, Ar-H), 5.8(lH,d,1O.5Hz, H-7), 5.4(1H,dd,105Hz,H-8),
4.8 (lH .d, 7.2Hz,H-5), 4. 1(lH,tn,H-6), 3.2(3H, .n, H-9, H-lO),
2.4(3H,s,N-CH3), 2.3-2.6(2H,tn,H-16), 1.7(2H,m, H-15)
2a 6.5-6.7(3H,m,Ar-H,H-8), 6.15( IH,d,10.8Hz,H-7), 468( IH,s,H-5),
3.8(3H, S,-OCH3), 3.32( lH,m, H-9), 304(2H,m,H-I 0), 2.44(3H,s,N-
CH3), 2.2-2.4 (2H,m, H-16)
2b 6.6(2H,ABq, Ar-H), 5.9(lH,d,7.2Hz, H-7), 5.48(1I:f,dd, H-8),
4.88(lH,d, 7.2Hz,H-5), 4.64(lH,m,H-6), 3.84(3H,s,-OCH3), 3-
3.33(3H, m, H-9, H-lO), 2.4(3H,s,N-CH3), 2.2-23(2H,m,H-16), 1.6-
18(2H,m, H-15)
3a 6.5-6.8 (3H, m, Ar-H, H-8), 6.2(lH, d, 9Hz, H-7), 4.7(lH, s, H-5) ,
3.3(2H,m,H-9, H-IO), 2.2-2.7(4H,m,H-16,N-CH2), 1.7(2H,d,9Hz,H-
15), 1.1(3H,t,CH3 of N-Et)
4a 6.5-6.8(3H,m,Ar-H,H-8), 6.2(lH,d,9Hz,H-7), 4.7(lH,s,H-5), 3.3(3H,
m,H-9, H-lO), 2.2-2.7( 4H,m,H-16.N-CH2), l.3-1.7( 4H,m,H-15,-CH2-
of N-Pr), 0.95(3H,t,CH3 ofN-Pr)
Sa 6.6-6.8(3H,m,Ar-H,H-8), 6. I 5(lH,d,9Hz,H-7), 4.7(lH,s,H-5) 3-
3.3(3H, m, H-9, H-lO), 2.2-2.7(4H,m,H-16,N-CH2-), 1.2-1.7(6H,m,H-
15,-CH2-CH2- of N-Bu), 0.9(3H,t,CH3 of N-Bu)
6a 6.5-6.8(3H,m,Ar-H,H-8), 6.2(lH,d,9Hz,H-7), 4.7(lH,s,H-5), .85
(3H,s, OCH3), 3-3.3(3H,m,H-9, H-lO), 2.3-2.7(4H,m,H-16,N-CH2-),
1.6-1.8(2H, rn, H-15),18(3H,t,CH3 of N-Et)
7a 6.64(2H,ABq,Ar-H), 4.64(lH,s,H-5), 2.9-3.3(3H,m,H-9,H-IO), 2.48
(3H,S,N-CH3), 2.2-2.8(5H,m,H-7,H-14,H-16), 16-2( 4H,m,H-8,H-15)
8a 6.68(2H,ABq, Ar-H), 4.66(lH,s,H-5), 3.92(3H,s,OCH3), 2.6-
3.3(4H,m,H-9,H-14,H-IO), 2.28(3H,s,N-CH3), 1.2-2.3(8H,m,H-7,H-
8,H-15,H-16)
mlz 299 (M'", 100%),215 (M'"-
CJf402, 40%). HRMS: C17H17N04
requires 299.1158. Found 299.1161
mlz 301 (M'", 100%),215 (M'"-
CJf602, 30%). HRMS: C17H'9N04
requires 301.1314 . Found 301. 1336
m/z 313 (M'", 100%), 299 (M'"-
CJf~02, 40%)
mlz 315 (M'", 100%),299 (M'"-
CJf602,38%)
m/z 313 (M'", 100%),299 (M'"-
CJf402, 50%)
m/z 327 (M'", 100%),243 (M'"-
CJf402,30%)
m/z 341 (M'", 100%),257 (M'"-
CJf402,33%)
m/z 327 (M'", 100%),243 (M'"-
C4H402,50%)
m/z 285 (M'", 100%), 270 (M'"-CH3 ,
10%). HRMS: CI7H'9N03 requires
285.1365. Found 285.1359
m/z 299 (M'", 100%),284 (M'"-CH3,
14%). HRMS: C,gH2IN03 requires
299.1522. Found 299.1524
Compounds la-6a showed IR (nujo1)vmax at 3300-3600 for hydroxyl groups and at 1677-1686 em" for conjugated carbonyl
groups. 7a and 8a showed IR (nujol)vmax at 1720-1730 em for carbonyl groups.
752 INDIAN J CHEM, SEC.B, AUGUST 1998
'» "'~ '~;:,...' ;:,...' ;:,...'0 Bacillus sp 0 0R' \ R' • R'H h OH OHfi HCV fi0
R R' Yield(%)
1 H CH) 94 (Ia) 2 (lb)
2 CH) CH) 53 (2a) 9 (2b)
3 H CH2CH) 43 (3a)
4 H CH2.CH2CH) 20 (4a)
5 H CH2(CH2hCH) 20 (Sa)
6 CH) CH2CH) 10 (6a)
SchemeI - Transformationof morphine 1a codeine2 and











Scheme ll-- Transformation of dihydromorphine7 and
dihydrocodeine8 byBacillus sp.
8a were identified as dihydromorphinone and
dihyrocodeinone, respectively (Scheme Il).
Metabolism of intermediates. Flasks containing 100
mL of mineral salts medium and 0.1% glucose were
inoculated and incubated as described in "Materials and
Methods". After 24hr, to one flask 14-hydroxycodeine
(2b, 10 109 in O.lmL methanol) and to another flask
codeinone (10 109 in O.lmL methanol) were added and
incubation continued for a further period of 3 days. At
the end of the incubation period, the contents of the
flasks were processed as described in "extraction of
metabolites". The crude extracts on HPLC analyses
indicated that 75% of the added codeinone was
transformed into 14-hydroxycodeinone 2a, whereas
only 10% of the added l-t-hydroxycodeine 2b was
transformed into 14-hydroxycodeinone 2a.
Experiments with cell-free extracts. Assays carried
out using cell-free extracts prepared from morphine
grown cells clearly showed the formation of 14-
hydroxymorphinone from morphine in the presence of
NAD+. TLC analysis showed the formation of one
metabolite with Rr O.72(system I) which is same as that
of la. It was further confirmed by HPLC analysis where
the enzymatically formed compound had the same
retention time as that of authentic 14-
hydroxymorphinone (Rt 3.5 min). HPLC analysis also
indicated that about 25% morphine was transformed
into 14-hydroxymorphinone. However, the cell free
extract did not contain any 17J3-hydroxysteroid
dehydrogenase activity as evidenced by its inability to
transform testosterone into androstenedione in the
presence of either NAD+ or NADP+. On the contrary,
cell-free extracts prepared from cells grown in the
presence of testosterone readily converted testosterone
to androstenedione in the presence of NAD+, whereas it
showed no activity against morphine. The
enzymatically formed compound with Rr 0.5 (system I)
was identified as androstenedione by comparing with an
authentic sample. It was further confirmed by HPLC
analysis where the enzymaticallly formed compound
had the same retention time (Rt 7.0 min) as that of
authentic androstenedione. HPLC analysis indicated
that over 90% of testosterone was transformed into
androstenedione. The cell-free extracts prepared from
cells grown only in the presence of glucose did not
show any activity against morphine as well as
testosterone suggesting that morphine dehydrogenase as
well as 17J3-hydroxysteroid dehydrogenase are
induciable in nature. Both morphine dehydrogenase and
17J3-hydrox,),steroiddehydrogenase of Bacillus sp.
showed absolute requirement for NAD+ for oxidation
and NAD+could not be replaced by NADP+.
Discussion
The present studies have clearly demonstrated that
the Bacillus sp. effectively carries out the oxidation of
the secondary alcoholic group at C-6 and 14-
hydroxylation in both morphine 1 and codeine 2
yielding 14-hydrox')'morphinone la and 14-
hydroxycodeinone 2a, respectively as major
transformation products (Scheme I). The minor
transformation products are 14-hydroxymorphine Ib
and 14-hydrox')'codeine 2b. Since codeinone is
transformed at significantly faster rate than 14-
hydroxycodeine 2b into 14-hydroxycodeinone 2a, it is
reasonable to assume that the oxidation of the
secondary alcoholic group at C-6 takes place prior to
allylic hydroxylation, Similar sequence of reactions has
been noticed earlier in the conversion of morphine and
codeine into 14-hydrox')'morphinone and 14-
hydroxycodeinone, respectively by Pseudomonas
testosteroni"'. In contrast, the ability of Pseudomonas
putida MlO to oxidise morphine and codeine into
morphinone and codeinone, respectively has been
reported". It was further demonstrated that a
constitutive NADH-dependent morphinone reductase
catalyses the reduction of the 7,8-double bond of
morphinone and codeinone'". However, the organism
failed to carry out l4-hydrox')'lation reaction. The
Bacillus sp. used in the present studies is devoid of
morphinone reductase activity. When dihydromorphine
7 and dihydrocodeine 8 were used as substrates, the
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organism readily transformed them only into
dihydromorphinone 7a and dihydrocodeinone Sa
respectively (Scheme II). This suggests that the 7,8-
double bond is a necessary structural feature to carry out
14-hydro~;ylation reaction.
We were interested to find out whether Bacillus sp.
still retains its ability to carry out oxidation of the
secondary alcoholic group at C-6 and hydroxylation at
C-14 if N-methyl group in morphine and codeine is
replaced by higher alkyl groups. It is known that the
physiological properties of morphine are altered greatly
with substitution on the N-atom and the length of the
N-alkyl chain is critical for exhibiting analgesic or
anti morphine properties". The present studies clearly
indicate that the organism retains its ability to carry out
oxidation of secondary hydroxyl group at C-6 position
and hydroxylation at C-14 position in all the N-variants
of morphine and codeine tested (Scheme I) although
these compounds are not good substrates for Bacillus
sp.
The hydroxysteroid dehydrogenase of Pseudomonas
testosteroni'" has been shown to transform morphine
into morphinone in the presence of NAD+. This is
different to what has been observed in the present
studies. The cell-free extract prepared from morphine
grown cells of Bacillus sp. contained an NAD+ -
dependent dehydrogenase active against morphine and
codeine, but failed to act on testosterone. However.
cells grown in the presence of testosterone contained
high levels of NAD+- dependent l713-hydro:\:ysteroid
dehydrogenase but devoid of morphine dehydrogenase
activity. These observations suggest that the NAD+-
dependent morphine dehydrogenase and hydroxysteroid
dehydrogenase in Bacillus sp. are different from each
other. Similar observations have been made earlier
with cell-free extracts prepared from morphine grown
cells of Pseudomonas putida M1019. Interestingly.
morphine dehydrogenase from Bacillus sp. and from
Pseudomonas putida MIO are having different pyridine
nucleotide specificity.
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